All-Oral Regimens -- The Future of Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Attendees at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco got a glimpse of the future of chronic hepatitis C therapy, as several researchers presented data from studies of all-oral direct-acting antiviral (DAA) regimens -- without interferon and its notoriously difficult side effects.
NEJM: High SVR Rate with Daclatasvir + Asunaprevir
AASLD: Daclatasvir + Asunaprevir Suppresses HCV in Null Responders
AASLD: PSI-7977 + Ribavirin Cures Hepatitis C in 12 Weeks
AASLD: BI 201355 + BI 201127 + Ribavirin Looks Good in SOUND-C